Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX): 7 pipeline candidates · 3 upcoming catalysts · ~13 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.0 months
D/E -9.75 · 7% dilution
Lead: Phase 2/Phase 3
7 candidates
3 upcoming, next in ~1048d
N/A
A transparent, data-derived signal for Inhibrx Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$161.7M
Quarterly Burn
$38.0M
Runway
13.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| inbrx-106 | Phase 2/Phase 3 |
| inbrx-106 - hexavalent ox40 agonist antibody | Phase 2/Phase 3 |
| inbrx-109 | Phase 2/Phase 3 |
| leucovorin | Phase 1 |
| ozekibart | Phase 2 |
| pemetrexed 500 mg/m2 | Phase 1/Phase 2 |
| trifluridine + tipiracil | Phase 1 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
134
Total value held
$845.0M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 2,885,414 | $194.0M |
| viking global investors lp | 1,437,705 | $96.7M |
| morgan stanley | 1,263,078 | $84.9M |
| vanguard capital management llc | 972,844 | $65.4M |
| blackrock, inc. | 798,898 | $53.7M |
| woodline partners lp | 768,866 | $51.7M |
| state street corp | 550,845 | $37.0M |
| millennium management llc | 327,860 | $22.0M |
| pfm health sciences, lp | 305,431 | $20.5M |
| schonfeld strategic advisors llc | 254,827 | $17.1M |
Showing top 10 of 134 institutional holders of Inhibrx Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Inhibrx Biosciences, Inc.'s pipeline?
Inhibrx Biosciences, Inc. (INBX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inhibrx Biosciences, Inc.'s lead drug candidate?
Inhibrx Biosciences, Inc.'s most advanced tracked candidate is inbrx-106 (Phase 2/Phase 3) for Head and Neck Squamous Cell Carcinoma (HNSCC).
What is Inhibrx Biosciences, Inc.'s next catalyst?
Inhibrx Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First" — expected May 1, 2029.
What is Inhibrx Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Inhibrx Biosciences, Inc. has approximately 13.0 months of cash runway.
What is Inhibrx Biosciences, Inc.'s market capitalization?
Inhibrx Biosciences, Inc.'s market capitalization is approximately $1.4B.
Get the full picture on Inhibrx Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.